What We're Reading: Page
Industry reads hand-picked by our editors
Feb 24, 2015
-
Business Wire
FDA to review Pfizer's rare lung disease drug for women
-
UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout
-
Compounding pharmacies chafe at FDA's disciplinary actions
-
-
Corgenix's 15-minute Ebola test approved by WHO
-
-
-
Holoclar makes history: Europe approves West's first stem-cell therapy
-
Cellectis files $115M IPO to fund unique CAR-T program
-
Feb 23, 2015
Feb 20, 2015
-
-
Biotech battle: Regeneron's Eylea bests Genenetch's Lucentis in head-to-head
-
Why FDA's label expansion for Celgene's Revlimid could foretell a global sales surge
-
-
-
Why so little uptake of preventive Truvada in the at-risk gay community?
-
Gilead's Harvoni supplants Sovaldi as top-selling launch drug
-
AstraZeneca's plan to unite R&D hubs takes flight
-
-
Feb 19, 2015
-
CVS fires controversial warning shot in opening salvo of PCSK9 price wars
-
The more, the merrier? Endo also pursuing Salix Pharma bid
-
-
-
Inotek slashes share price ahead of IPO
-
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
-
GSK replaces US pharma ops head Connelly amid struggles
-
AstraZeneca's plan to unite R&D hubs takes flight
-
Shanghai official to serve 19 years over GSK bribery case
-
Feb 18, 2015
-
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
-
GSK replaces US pharma ops head Connelly amid struggles
-
-
Can AZ finally solidify a deal for its anti-infectives unit?
-
Profits fall for India's largest drug maker
-
NAFTA patent spat rages on between Canada and Lilly
-
-
Eisai, Pfizer, and Novartis meds get FDA love over the long weekend
-
-
Feb 17, 2015
-
-
Shire raises 2015 forecast on NPS acquisition
-
-
-
AZ to settle Nexium kickback case for $7.9M
-
Teva's internal probe turns up 'likely' corruption
-
Valeant arranges financing for potential Salix Pharma bid
-
Indian pharma giants scuffle to snap up injectables maker Claris
-
-
Feb 13, 2015
-
-
UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg
-
Hospira CEO's golden parachute for Pfizer deal: $80 million
-
-
-
GSK broadens vax portfolio with $190M GlycoVaxyn deal
-
Chinese researchers develop nanocarrier for pancreatic cancer drug
-
-
-
Riken stem cell saga continues as Obokata and other scientists face reprimands
Previous
